Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study

Rasmus Bo Jansen; Tomas Møller Christensen; Jens Bülow; Lene Rørdam; Per E Holstein; Niklas Rye Jørgensen; Ole Lander Svendsen

doi:10.1016/j.jdiacomp.2017.11.004

Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study

Rasmus Bo Jansen, Tomas Møller Christensen, Jens Bülow, Lene Rørdam, Per E Holstein, Niklas Rye Jørgensen, Ole Lander Svendsen

7 Citations (Scopus)

Abstract

BACKGROUND AND AIMS: Charcot foot is a rare but severe complication to diabetes and peripheral neuropathy. It is still unclear if an acute Charcot foot has long-term effects on the bone metabolism. To investigate this, we conducted a follow-up study to examine if a previously acute Charcot foot has any long-term effects on bone mineral density (BMD) or local or systemic bone metabolism.

METHODS: An 8.5-year follow-up case-control study of 44 individuals with diabetes mellitus, 24 of whom also had acute or chronic Charcot foot at the baseline visit in 2005-2007, who were followed up in 2015 with DXA scans and blood samples.

RESULTS: 21 of the 44 baseline participants participated in the follow-up. There were no difference in the change in total hip BMD from baseline to follow-up in either the Charcot or the control group (p = 0.402 and 0.517), and no increased risk of osteoporosis in the previous Charcot feet either. From baseline to follow-up, there was a significant difference in the change in levels of fsRANK-L in the Charcot group, but not in the control group (p = 0.002 and 0.232, respectively). At follow-up, there were no differences in fsRANK-L between the groups. The fsRANK-L/OPG ratio also significantly decreased from baseline to follow-up in the Charcot group (3.4 versus 0.5) (p = 0.009), but not in the control group (1.3 versus 1.1) (p = 0.302).

CONCLUSION: We found that diabetes patients with an acute Charcot foot have an elevated fsRANK-L/OPG ratio, and that the level decreased from baseline to follow-up to be comparable to the level in diabetes patients without previous or current Charcot foot. We found no permanent effect of an acute Charcot foot on hip or foot BMD.

Original language	English
Journal	Journal of Diabetes and its Complications
Volume	32
Issue number	2
Pages (from-to)	164-170
Number of pages	7
ISSN	1056-8727
DOIs	https://doi.org/10.1016/j.jdiacomp.2017.11.004
Publication status	Published - Feb 2018

Keywords

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jdiacomp.2017.11.004

Cite this

Jansen, R. B., Christensen, T. M., Bülow, J., Rørdam, L., Holstein, P. E., Jørgensen, N. R., & Svendsen, O. L. (2018). Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study. Journal of Diabetes and its Complications, 32(2), 164-170. https://doi.org/10.1016/j.jdiacomp.2017.11.004

Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study. / Jansen, Rasmus Bo; Christensen, Tomas Møller; Bülow, Jens et al.
In: Journal of Diabetes and its Complications, Vol. 32, No. 2, 02.2018, p. 164-170.

Research output: Contribution to journal › Journal article › Research › peer-review

Jansen, RB, Christensen, TM, Bülow, J, Rørdam, L, Holstein, PE, Jørgensen, NR & Svendsen, OL 2018, 'Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study', Journal of Diabetes and its Complications, vol. 32, no. 2, pp. 164-170. https://doi.org/10.1016/j.jdiacomp.2017.11.004

@article{cea6d599df3744739e884b8576bc3962,

title = "Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study",

abstract = "BACKGROUND AND AIMS: Charcot foot is a rare but severe complication to diabetes and peripheral neuropathy. It is still unclear if an acute Charcot foot has long-term effects on the bone metabolism. To investigate this, we conducted a follow-up study to examine if a previously acute Charcot foot has any long-term effects on bone mineral density (BMD) or local or systemic bone metabolism.METHODS: An 8.5-year follow-up case-control study of 44 individuals with diabetes mellitus, 24 of whom also had acute or chronic Charcot foot at the baseline visit in 2005-2007, who were followed up in 2015 with DXA scans and blood samples.RESULTS: 21 of the 44 baseline participants participated in the follow-up. There were no difference in the change in total hip BMD from baseline to follow-up in either the Charcot or the control group (p = 0.402 and 0.517), and no increased risk of osteoporosis in the previous Charcot feet either. From baseline to follow-up, there was a significant difference in the change in levels of fsRANK-L in the Charcot group, but not in the control group (p = 0.002 and 0.232, respectively). At follow-up, there were no differences in fsRANK-L between the groups. The fsRANK-L/OPG ratio also significantly decreased from baseline to follow-up in the Charcot group (3.4 versus 0.5) (p = 0.009), but not in the control group (1.3 versus 1.1) (p = 0.302).CONCLUSION: We found that diabetes patients with an acute Charcot foot have an elevated fsRANK-L/OPG ratio, and that the level decreased from baseline to follow-up to be comparable to the level in diabetes patients without previous or current Charcot foot. We found no permanent effect of an acute Charcot foot on hip or foot BMD.",

keywords = "Journal Article",

author = "Jansen, {Rasmus Bo} and Christensen, {Tomas M{\o}ller} and Jens B{\"u}low and Lene R{\o}rdam and Holstein, {Per E} and J{\o}rgensen, {Niklas Rye} and Svendsen, {Ole Lander}",

year = "2018",

month = feb,

doi = "10.1016/j.jdiacomp.2017.11.004",

language = "English",

volume = "32",

pages = "164--170",

journal = "Journal of Diabetes and its Complications",

issn = "1056-8727",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot

T2 - An 8.5-year prospective case-control study

AU - Jansen, Rasmus Bo

AU - Christensen, Tomas Møller

AU - Bülow, Jens

AU - Rørdam, Lene

AU - Holstein, Per E

AU - Jørgensen, Niklas Rye

AU - Svendsen, Ole Lander

PY - 2018/2

Y1 - 2018/2

N2 - BACKGROUND AND AIMS: Charcot foot is a rare but severe complication to diabetes and peripheral neuropathy. It is still unclear if an acute Charcot foot has long-term effects on the bone metabolism. To investigate this, we conducted a follow-up study to examine if a previously acute Charcot foot has any long-term effects on bone mineral density (BMD) or local or systemic bone metabolism.METHODS: An 8.5-year follow-up case-control study of 44 individuals with diabetes mellitus, 24 of whom also had acute or chronic Charcot foot at the baseline visit in 2005-2007, who were followed up in 2015 with DXA scans and blood samples.RESULTS: 21 of the 44 baseline participants participated in the follow-up. There were no difference in the change in total hip BMD from baseline to follow-up in either the Charcot or the control group (p = 0.402 and 0.517), and no increased risk of osteoporosis in the previous Charcot feet either. From baseline to follow-up, there was a significant difference in the change in levels of fsRANK-L in the Charcot group, but not in the control group (p = 0.002 and 0.232, respectively). At follow-up, there were no differences in fsRANK-L between the groups. The fsRANK-L/OPG ratio also significantly decreased from baseline to follow-up in the Charcot group (3.4 versus 0.5) (p = 0.009), but not in the control group (1.3 versus 1.1) (p = 0.302).CONCLUSION: We found that diabetes patients with an acute Charcot foot have an elevated fsRANK-L/OPG ratio, and that the level decreased from baseline to follow-up to be comparable to the level in diabetes patients without previous or current Charcot foot. We found no permanent effect of an acute Charcot foot on hip or foot BMD.

AB - BACKGROUND AND AIMS: Charcot foot is a rare but severe complication to diabetes and peripheral neuropathy. It is still unclear if an acute Charcot foot has long-term effects on the bone metabolism. To investigate this, we conducted a follow-up study to examine if a previously acute Charcot foot has any long-term effects on bone mineral density (BMD) or local or systemic bone metabolism.METHODS: An 8.5-year follow-up case-control study of 44 individuals with diabetes mellitus, 24 of whom also had acute or chronic Charcot foot at the baseline visit in 2005-2007, who were followed up in 2015 with DXA scans and blood samples.RESULTS: 21 of the 44 baseline participants participated in the follow-up. There were no difference in the change in total hip BMD from baseline to follow-up in either the Charcot or the control group (p = 0.402 and 0.517), and no increased risk of osteoporosis in the previous Charcot feet either. From baseline to follow-up, there was a significant difference in the change in levels of fsRANK-L in the Charcot group, but not in the control group (p = 0.002 and 0.232, respectively). At follow-up, there were no differences in fsRANK-L between the groups. The fsRANK-L/OPG ratio also significantly decreased from baseline to follow-up in the Charcot group (3.4 versus 0.5) (p = 0.009), but not in the control group (1.3 versus 1.1) (p = 0.302).CONCLUSION: We found that diabetes patients with an acute Charcot foot have an elevated fsRANK-L/OPG ratio, and that the level decreased from baseline to follow-up to be comparable to the level in diabetes patients without previous or current Charcot foot. We found no permanent effect of an acute Charcot foot on hip or foot BMD.

KW - Journal Article

U2 - 10.1016/j.jdiacomp.2017.11.004

DO - 10.1016/j.jdiacomp.2017.11.004

M3 - Journal article

C2 - 29196119

SN - 1056-8727

VL - 32

SP - 164

EP - 170

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

IS - 2

ER -

Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this